India covid-19 vaccine infection Analysis India

Bharat Biotech's Covaxin found 100% effective against 'severe Covid disease' in Phase-3 interim analysis

Reading now: 434
www.livemint.com

Covaxin, the first made-in-India coronavirus vaccine.In the trial results, Bharat Biotech and the ICMR said that Covaxin demonstrates an overall interim clinical efficacy of 78%.

The efficacy against severe Covid-19 disease was 100%, the company said.The second interim analysis is based on accruing more than 87 symptomatic cases of Covid-19.

Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% against mild, moderate, and severe Covid-19 disease, the company said.The efficacy against severe Covid-19 disease was 100%, with an impact on reduction in hospitalisations.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA